Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors. Elevated levels of serotonin contribute to the gastrointestinal and possibly other symptoms experienced by these patients.

In addition to LX1032, Lexicon has three other drug candidates progressing through various stages of clinical development, including LX1031 for irritable bowel syndrome, LX2931 for rheumatoid arthritis, and LX4211 for diabetes. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

"This is an important study, designed to evaluate LX1032's effect on the gastrointestinal symptoms experienced by patients with carcinoid syndrome who have become refractory to current treatment options," said Philip M. Brown, M.D., J.D., senior vice president of clinical development at Lexicon. "We are encouraged by the clinical results obtained to date in which LX1032 demonstrated potent reductions in serotonin production in healthy volunteers."

The Phase 2 clinical trial is designed as a four-week, randomi
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- , The first grants awarded to ... (ESPE) Meeting  Investment supports innovative projects for ... field of growth  , EMD Serono, a ... , today announced the first recipients of the Grant ... announced during a Satellite Symposium organized by EMD Serono ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2
... EU Citizens (6%) Have Liver Diseases, 5th Most Common Cause of ... ... Abuse Takes 13,000,Number With Fatty Liver Disease Stable or Growing; Viral Hepatitis Declines, ... world gathered today in this historic Italian,city to attend the opening sessions of ...
... one for analyzing tumors , Doctors treating individuals with ... oxygen in a tumor very useful, because low levels of oxygen ... new method to do this and to image the surrounding organs ... to image tumors in mice by Murali Krishna and colleagues, at ...
... the biggest-selling,biologics developed during the boom years in biotech ... have lost patent,protection in the U.S. in 2007 or ... This opens up a huge potential market for biosimilars, ... report by Kalorama,Information, Biogenerics: the World Market for Biosimilars., ...
Cached Biology Technology:Liver Diseases: A Huge European Health Burden, But Some Trends are Positive 2Liver Diseases: A Huge European Health Burden, But Some Trends are Positive 3JCI table of contents: April 22, 2008 2JCI table of contents: April 22, 2008 3JCI table of contents: April 22, 2008 4JCI table of contents: April 22, 2008 5JCI table of contents: April 22, 2008 6JCI table of contents: April 22, 2008 7JCI table of contents: April 22, 2008 8JCI table of contents: April 22, 2008 9JCI table of contents: April 22, 2008 10JCI table of contents: April 22, 2008 11JCI table of contents: April 22, 2008 12Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles 2
(Date:9/18/2014)... to undertake jaunts into the countryside each year could come ... century, according to new research. , Climate change could postpone ... as summer temperatures linger later into the year, Princeton University ... . For instance, the paper birch a popular foliage ... could change color one to three weeks later by the ...
(Date:9/18/2014)... 18, 2014 -- Arizona turned its newborn screening program into ... short months, earning it the first-ever Newborn Screening Quality Award ... Dimes presented Will Humble, M.P.H., Arizona,s Department of Health Services ... Mr. Humble established a policy of full transparency for the ... blood samples to the lab for analysis, and set a ...
(Date:9/18/2014)... The tropical rabbitfish which have devastated algal forests in ... the entire Mediterranean basin if their distribution continues to ... The study, by an international team of researchers led ... Fiona Tomas of the Mediterranean Institute for Advanced Studies ... Ecology ., Members of the team surveyed more than ...
Breaking Biology News(10 mins):Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... has landed a University of Central Florida scientist more ... could have profound benefits in the search for cures ... Annette Khaled is conducting research into what triggers the ... surrounding cells. If its secrets could be unlocked and ...
... Contaminated seaweeds in Sydney Harbour could be threatening the small ... revealing that the harbour,s seaweeds have the world,s highest levels ... of the offspring of small crustaceans that feed on a ... exposed to copper at levels found in some parts of ...
... early diagnosis of Alzheimers, Parkinsons and other diseases has ... Jersey Technology Council competition. Based at NJITs business ... , a start-up company, was named most likely to ... entrepreneurs and investors. NeuroTrax develops ...
Cached Biology News:'Death protein' research secures funding for UCF scientists 2Sydney harbors deadly diet for sea creatures 2NJIT start-up company NeuroTrax named best in show 2
...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
... are designed for ultra-sensitive detection of ... PVDF membranes. Since all necessary reagents ... antibodies), the WesternBreeze Kits save you ... and getting your final results. Solutions ...
Biology Products: